UNSPSC 51286707: Tetroxoprim

This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C16H22N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5R6712AY0K, chemically known as 2,4-pyrimidinediamine, 5-((3,5-dimethoxy-4-(2-methoxyethoxy)phenyl)methyl)- but more generally known as tetroxoprim, which bears US NIH Compound Identifier 65450. European Medicines Agency schedules Tetroxoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10953MIG.

The term TETROXOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 29, No. 10 1975, List 15). TETROXOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51286707 Tetroxoprim is a Commodity code that nominally identifies a single pharmaceutical product, yet recent state and local solicitations tagged with this code show minimal actual procurement of tetroxoprim itself. Instead, the opportunities reveal that state and local governments are buying a broader range of pharmaceuticals and related health-supply categories—naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products—through volume purchasing and cooperative agreements. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal fire and rescue services (City of Tampa), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota), reflecting the diversity of public health and emergency-response procurement across jurisdictions. Scope ranges from direct product supply agreements with fixed pricing and quarterly deliveries to market-research RFIs exploring direct-to-manufacturer prescription programs and competitive bids for emergency medical supplies.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP extending multistate reach to Oregon. Recent representative opportunities include Seminole County's IFB60459723LAS (IFB for naloxone and drug deactivation systems, due July 26, 2023), the City of Tampa's 26P00145 (IFB for medical and first aid supplies, estimated at $700,000, due March 13, 2026), the Texas HHS Commission's HHS0017013 (RFI on direct-to-manufacturer prescriptions, due April 3, 2026), and MMCAP's S1070000015802 (RFP for generic pharmaceuticals and OTC products, due March 26, 2026). The code shows limited true tetroxoprim activity and appears to be a tagging artifact; actual procurement focuses on emergency pharmaceuticals, medical consumables, and supply-chain innovation around pharmacy benefit programs.